BioSpace News Archive

BioCapital

Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale

Aditxt®, Inc. is pleased to provide an important update regarding its innovation programs and strategic M&A initiatives.

August 18, 2023
·
9 min read
Drug Development

Amber Ophthalmics Announces First Patient Enrolled in NEXPEDE-1, a Phase 2/3 Clinical Trial Evaluating Nexagon for the Treatment of Persistent Corneal Epithelial Defects

Amber Ophthalmics, Inc. (Amber) , a privately held, clinical stage biopharmaceutical company, announced today that Dr. Mark S. Gorovoy from Gorovoy M.D. Eye Specialists has enrolled the first patient in the AMB-01-006 (NEXPEDE-1) study.

August 18, 2023
·
2 min read
Business

Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board

Dr. Landau joins the Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Memorial Sloan Kettering Cancer Center.

August 18, 2023
·
6 min read
Business

Medivir AB - Interim Report January - June 2023

Continued strong momentum and promising signs of patient benefit in the combination study with fostrox and Lenvima®.

August 18, 2023
·
5 min read
Drug Development

Inmagene’s anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study

Inmagene Biopharmaceuticals announced topline results from a Phase 1 study of IMG-007, an anti-OX40 monoclonal antibody (mAb).

August 18, 2023
·
4 min read
Policy

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy

Calliditas Therapeutics AB, announced that the U.S. Food and Drug Administration has accepted the submission for the supplemental New Drug Application for TARPEYO® delayed release capsules and granted Priority Review.

August 18, 2023
·
11 min read
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

Can-Fite BioPharma Ltd today announced that it submitted a pediatric study plan to the U.S. Food and Drug Administration (FDA) for the treatment of adolescents suffering from psoriasis with Piclidenoson.

August 18, 2023
·
6 min read
BioCapital

Zalgen Immunotherapeutic Confers Complete Protection Against Advanced Multilineage Lassa Infections in Nonhuman Primates

Zalgen Labs LLC today announced publication of data demonstrating that Arevirumab-3®, its lead immunotherapeutic candidate, is an effective therapeutic for the treatment of Lassa virus infections, with activity against all major viral lineages that cause severe disease in humans, and at very low dosages.

August 18, 2023
·
4 min read
Business

Nexcella Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board

Dr. Landau joins the Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Memorial Sloan Kettering Cancer Center.

August 18, 2023
·
5 min read